Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking

Gynecologic Oncology

Volumn 106, Issue 1, 2007, Pages 160-163

  Le, T ^a   Williams, K ^a   Senterman, M ^a   Hopkins, L ^a   Faught, W ^b   Fung Kee Fung, M ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Composite pathologic tumour response score; Neoadjuvant chemotherapy; Prognosis

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GYNECOLOGIC CANCER; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 34250167227     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.03.029     Document Type: Article

References (15)

1. Hoskins W.J., Perez C.A., and Young R.C. Principles and practice of gynecologic oncology (2000), Lippincott Williams & Wilkins, Philadelphia, PA
2. DiSaia P.J., and Creasman W.T. Clinical gynecologic oncology (2002), Mosby, St. Louis, MO
3. Chan J.K., Cheung M.K., Husain A., et al. Patterns and progress in ovarian cancer over 14 years. Obstet. Gynecol. 108 (2006) 521-528
4. Houghton A.N., Uchi H., and Wolchok J.D. The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell. 7 5 (2005) 403-405
5. Yoshida N., Abe H., Ohkuri T., Wakita D., et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int. J. Oncol. 28 5 (2006) 1089-1098
6. Welsh T.J., Green R.H., Richardson D., Waller D.A., et al. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol. 23 35 (2005) 8959-8967
7. Klintrup K., Makinen J.M., Kauppila S., Vare P.O., et al. Inflammation and prognosis in colorectal cancer. Eur. J. Cancer 41 17 (2005) 2645-2654
8. Funada Y., Noguchi T., Kikuchi R., Takeno S., et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep. 10 2 (2003) 309-313
9. Ohno S., Inagawa H., Dhar D.K., Fujii T., et al. Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the impact on FasL-mediated counterattack. Anticancer Res. 25 1B (2005) 463-470
10. Le T., Hopkins L., and Fung Kee Fung M. Quality of life assessments in epithelial ovarian cancer patients during and after chemotherapy. Int. J. Gynecol. Cancer 15 5 (2005) 811-816
11. Hegazy M.A., Hegazi R.A., Elshafei M.A., Setit A.E., et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J. Surg. Oncol. 3 (2005 Aug 31) 57-61
12. Vergote I., De Wever I., Tjalma W., Van Gramberen M., et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 71 3 (1998) 431-436
13. Kuhn W., Rutke S., Spathe K., Schmalfeldt B., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92 10 (2001) 2585-2591
14. Lee S.J., Kim B.G., Lee J.W., Park C.S., et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J. Obstet. Gynaecol. Res. 32 1 (2006) 99-106
15. Steed H., Oza A.M., Murphy J., Laframboise S., et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int. J. Gynecol. Cancer 16 Suppl. 1 (2006) 47-53